United-Guardian, Inc. — 2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019; this is an annual report, not a quarterly filing. The company manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products through its Guardian Laboratories division. It operates as one business segment.
Financial performance and position
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Net sales | $13.60 million | $13.45 million | Up 1% |
| Gross margin | 58% | 60% | Down 2 percentage points |
| Operating income | $5.40 million | $5.58 million | Down $183,878 |
| Net income | $4.76 million | $4.35 million | Up 9% |
| Basic and diluted EPS | $1.04 | $0.95 | Up $0.09 |
| Cash from operations | $4.48 million | $4.95 million | Down $474,301 |
- Net income benefited from a $431,076 gain on marketable securities, compared with a $333,138 loss in 2018. Investment income declined 12% to $203,329. The securities gain materially contributed to the improvement in reported earnings.
- Gross margin fell as Renacidin, a lower-margin product, grew to 26% of sales from 22% in 2018.
- Cash and cash equivalents were $1.05 million and marketable securities were $6.87 million at year-end. Working capital was $10.22 million; the current ratio was 8.6. The balance sheet reports no debt.
- Accounts receivable increased 25% to $2.10 million; days sales outstanding rose to 51 from 49. Inventory declined to $1.22 million from $1.48 million.
- Investing activities provided $1.07 million, mainly reflecting marketable securities sales. Financing activities used $5.05 million, all reported as dividends paid. The company declared $1.10 per share in 2019, versus $1.05 in 2018.
Material changes and business mix
- Cosmetic ingredient sales fell 15% to $6.38 million, principally because of lower Lubrajel sales to Ashland Specialty Ingredients (ASI) and other marketing partners. Lower demand in China and competition from lower-priced Asian products were key factors.
- Pharmaceutical sales rose 17% to approximately $4.09 million; Renacidin sales increased 19% to $3.49 million, which management attributed in part to increased online promotion. Clorpactin sales rose approximately 4%.
- Medical-product sales increased 33% to $2.97 million, including a 58% increase in Lubrajel MG sales. Industrial and other sales declined 7% to $161,138.
- Lubrajel products and Renacidin together represented approximately 93% of 2019 sales. ASI accounted for approximately 36% of gross sales; two distributors and marketing partners together represented 52% of gross sales. ASI’s marketing agreement renewed through December 31, 2021, subject to its termination provisions.
- Operating expenses rose 1% to $2.15 million; R&D expense was $397,391, essentially unchanged. The effective tax rate increased to approximately 21.1% from 20.4%.
Outlook, risks, and other notable items
- The company provided no quantified sales or earnings guidance. It expects 2020 R&D spending to be comparable to 2019 and planned to launch Lubrajel Oil PF in April 2020; other product-development projects remained at varying stages and may not become commercial products.
- Management said working capital was sufficient for the next fiscal year and reported no material commitments for future capital expenditures. Long-term liquidity depends on generating cash from profitable operations.
- The filing, dated March 18, 2020, cautioned that the coronavirus outbreak could reduce customer demand, delay payments, disrupt raw-material supply, or cause temporary shutdowns. The extent of the impact was not then determinable; production had not yet been affected. The company was building inventory for certain materials with limited sourcing alternatives.
- Other key risks include pricing pressure and currency-related competitiveness in foreign markets, reliance on marketing partners and a concentrated customer base, possible customer credit deterioration, and dependence on major raw-material vendors. Six vendors supplied approximately 86% of 2019 raw-material purchases.
- The company reported no legal proceedings or off-balance-sheet arrangements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not provide an internal-control attestation. The 2019 financial statements received an unmodified audit opinion from Baker Tilly, which served as auditor beginning in 2019.
Important facts for investors to verify
- Whether Renacidin growth and the improvement in net income persist, distinguishing operating performance from volatile investment gains and losses.
- Whether cosmetic ingredient sales recover amid lower-priced competition, particularly in China, and what the coronavirus disruption ultimately meant for demand, collections, and supply.
- How customer and distributor concentration, including ASI’s role, affects sales and receivable exposure; confirm the continuation and terms of the ASI agreement.
- Whether the $1.10-per-share annual dividend is sustainable relative to operating cash generation and liquidity needs.
- The filing’s product-category disclosures include both net-sales figures and separate gross-sales/discount-and-allowance figures; use the appropriate basis when comparing product mix or growth.